Today, we will see why Oyster Point Pharma (OYST) is an attractive investment opportunity in 2020.
Company overview
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative treatments targeting ocular surface diseases. The company’s lead asset is OC-01, an investigational drug candidate and highly selective nAChR (nicotinic acetylcholine receptors agonist). The therapy is being developed as a nasal spray to treat the signs and symptoms of DED (dry eye disease). The company also plans to study OC-01 in NK (neurotrophic keratitis) indication, a degenerative disease in